Edgewood's $20M Series A; Nanoscope to pursue FDA approval for eye gene therapy later this year
26 Mar 2024
Phase 2Gene Therapy
Plus, news about bluebird bio, Q32 Bio and Aquestive Therapeutics:
Edgewood Oncology’s $20M Series A:
The Brookline, MA-based biotech plans to use the money to
support
Phase 2a studies in acute myeloid leukemia and targeted breast cancer. It’s financed by Alta Partners.
— Kyle LaHucik
Nanoscope to seek FDA approval for eye gene therapy:
The Dallas-based biotech
said
its mutation-agnostic gene therapy MCO-010 passed a Phase 2b study in retinitis pigmentosa, significantly improving vision measured on an eye chart at one year at both the high and low doses compared to a sham control. It expects to submit an application for MCO-010 to the FDA in the second half of this year.
— Lei Lei Wu
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.